Samso is drawn to NeuroScientific because the Company is transitioning from early-stage development into real-world clinical validation. The Special Access Program outcomes represent a tangible inflection point, where clinical efficacy, regulatory engagement, and manufacturing readiness begin to converge around a scalable therapeutic platform.

NeuroScientific Biopharmaceuticals Ltd (ASX:NSB) has made a decisive move with its proposed acquisition of StemSmart™, a patented mesenchymal stromal cell (MSC) technology. This isn’t just another biotech transaction — it signals a strategic leap into the fast-growing field of regenerative medicine, positioning NSB to capitalise on one of the most promising frontiers in modern healthcare.